The General Hospital Corporation;The Broad Institute Inc.;Dana-Farber Cancer Institute, Inc.
发明人:
Fritsch, Edward F.,Hacohen, Nir,Rooney, Michael Steven,Shukla, Sachet Ashok,Wu, Catherine J.,Bachireddy, Pavan,Sun, Jing
申请号：
AU2016264623
公开号：
AU2016264623A1
申请日:
2016.05.20
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer； (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population； and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.
